Protocol Ledger

NCT04233801 · Phase III · COMPLETED

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Interventional Phase III clinical trial protocol NCT04233801 sponsored by Boehringer Ingelheim in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-04-15 Enrollment: 219 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04233801
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)219 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04233801
Protocol FieldVerified Registry Value
NCT IdentifierNCT04233801
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment219 participants (ACTUAL)
Registered Start Date2020-04-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI